{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=86",
    "query": {
      "intervention": "combined treatment",
      "page": 86
    },
    "page_size": 10
  },
  "pagination": {
    "page": 86,
    "page_size": 10,
    "total_count": 13993,
    "total_pages": 1400,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=87&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=85&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T22:46:36.120Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05128487",
      "title": "A Study of NDI 1150-101 in Patients With Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Renal Cell Carcinoma (Kidney Cancer)",
        "Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma",
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "NDI-101150",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nimbus Saturn, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2021-11-05",
      "completion_date": "2025-05",
      "has_results": false,
      "last_update_posted_date": "2024-11-25",
      "last_synced_at": "2026-11-04T22:46:36.120Z",
      "location_count": 19,
      "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05128487"
    },
    {
      "nct_id": "NCT02846506",
      "title": "A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Metformin Extended Release (XR)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 44,
      "start_date": "2016-08",
      "completion_date": "2016-10",
      "has_results": false,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-11-04T22:46:36.120Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02846506"
    },
    {
      "nct_id": "NCT06163534",
      "title": "A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Tempus AI",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2024-08-01",
      "completion_date": "2028-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-11-04T22:46:36.120Z",
      "location_count": 31,
      "location_summary": "Duarte, California • Los Angeles, California • Palo Alto, California + 25 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06163534"
    },
    {
      "nct_id": "NCT04396821",
      "title": "A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer",
        "Gastric Cancer",
        "Gastroesophageal-junction Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "TST001",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab Injection [Opdivo]",
          "type": "DRUG"
        },
        {
          "name": "mFOLFOX6",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Albumin-Bound Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Transcenta Therapeutics (Hangzhou) Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2020-05-28",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-11-04T22:46:36.120Z",
      "location_count": 18,
      "location_summary": "Gilbert, Arizona • Tucson, Arizona • New Haven, Connecticut + 14 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04396821"
    },
    {
      "nct_id": "NCT01859715",
      "title": "Emergency Department (ED) Drug Interaction in Emergency Department Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Drug Interactions"
      ],
      "interventions": [
        {
          "name": "Oxycodone",
          "type": "DRUG"
        },
        {
          "name": "Hydrocodone",
          "type": "DRUG"
        },
        {
          "name": "Ondansetron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "18 Years to 95 Years"
      },
      "enrollment_count": 502,
      "start_date": "2012-06",
      "completion_date": "2013-02",
      "has_results": true,
      "last_update_posted_date": "2016-05-05",
      "last_synced_at": "2026-11-04T22:46:36.120Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01859715"
    },
    {
      "nct_id": "NCT05583149",
      "title": "Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Refractory Aggressive B-cell Lymphomas",
        "Refractory B-Cell Non-Hodgkin Lymphoma",
        "Aggressive B-cell NHL",
        "Diffuse Large B-cell Lymphoma (DLBCL)",
        "De Novo or Transformed Indolent B-cell Lymphoma",
        "DLBCL, Nos Genetic Subtypes",
        "T Cell/Histiocyte-rich Large B-cell Lymphoma",
        "EBV-Positive DLBCL, Nos",
        "Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL)",
        "High-Grade B-Cell Lymphoma, Nos",
        "C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma",
        "Grade 3b Follicular Lymphoma",
        "C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "ACALABRUTINIB",
          "type": "DRUG"
        },
        {
          "name": "LISOCABTAGENE MARALEUCEL",
          "type": "DRUG"
        },
        {
          "name": "Lymphodepleting chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Patrick C. Johnson, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2023-03-01",
      "completion_date": "2029-03-01",
      "has_results": true,
      "last_update_posted_date": "2026-01-29",
      "last_synced_at": "2026-11-04T22:46:36.120Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05583149"
    },
    {
      "nct_id": "NCT01529593",
      "title": "Temsirolimus in Combination With Metformin in Patients With Advanced Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancers"
      ],
      "interventions": [
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "14 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2012-03-26",
      "completion_date": "2025-03-14",
      "has_results": false,
      "last_update_posted_date": "2025-03-24",
      "last_synced_at": "2026-11-04T22:46:36.120Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01529593"
    },
    {
      "nct_id": "NCT03197493",
      "title": "Extension, Carbidopa-levodopa in Neovascular Age-related Macular Degeneration (AMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Macula; Degeneration",
        "Retina"
      ],
      "interventions": [
        {
          "name": "carbidopa-levodopa 25-100 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Snyder, Robert W., M.D., Ph.D., P.C.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 35,
      "start_date": "2017-08-01",
      "completion_date": "2020-07-09",
      "has_results": true,
      "last_update_posted_date": "2025-09-12",
      "last_synced_at": "2026-11-04T22:46:36.120Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03197493"
    },
    {
      "nct_id": "NCT02528214",
      "title": "Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Oral corticosteroid therapy (prednisone/prednisolone)",
          "type": "DRUG"
        },
        {
          "name": "Inhaled corticosteroid (ICS) therapy",
          "type": "DRUG"
        },
        {
          "name": "Albuterol/Salbutamol",
          "type": "DRUG"
        },
        {
          "name": "Levalbuterol/Levosalbutamol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 210,
      "start_date": "2015-10-15",
      "completion_date": "2017-11-13",
      "has_results": true,
      "last_update_posted_date": "2019-10-01",
      "last_synced_at": "2026-11-04T22:46:36.120Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Rolling Hills Estates, California • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Amarillo",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02528214"
    },
    {
      "nct_id": "NCT01366547",
      "title": "Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects",
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir 50 mg",
          "type": "DRUG"
        },
        {
          "name": "abacavir 600 mg/lamivudine 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 18,
      "start_date": "2011-06",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2011-08-08",
      "last_synced_at": "2026-11-04T22:46:36.120Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01366547"
    }
  ]
}